If the BPCIA Should Fall – SCOTUS Decision Scenario Outlook
Monday, November 9, 2020
2:30 p.m. - 3:30 p.m.
While sometimes an afterthought in the enormous wake of the ACA, the legislative framework for biosimilars was passed as part of the landmark legislation and is in jeopardy pending the high court’s decision. Hear discussion around potential scenarios if the BPCIA were to be repealed as a result of a ruling against the ACA.
Moderator: Christine Simmon
Senior Vice President, Policy & Strategic Alliances, AAM
Executive Director, Biosimilars Council
Partner, Mehlman Castagnetti, Rosen & Thomas
Chad Landmon, J.D.
Partner, Axinn, Veltron & Harkrider LLP